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CD69 is involved in immune cell homeostasis, regulating the T cell-mediated immune response through the control of Th17 cell
differentiation. However, natural ligands for CD69 have not yet been described. Using recombinant fusion proteins containing
the extracellular domain of CD69, we have detected the presence of a ligand(s) for CD69 on human dendritic cells (DCs). Pull-
down followed bymass spectrometry analyses of CD69-binding moieties on DCs identified galectin-1 as a CD69 counterrecep-
tor. Surface plasmon resonance and anti-CD69 blocking analyses demonstrated a direct and specific interaction between CD69
and galectin-1 that was carbohydrate dependent. Functional assays with both human andmouse T cells demonstrated the role of
CD69 in the negative effect of galectin-1 on Th17 differentiation. Our findings identify CD69 and galectin-1 to be a novel regula-
tory receptor-ligand pair that modulates Th17 effector cell differentiation and function.
CD69, a C-type lectin, is a member of the natural killer (NK)receptor family and is induced early following activation of
leukocytes (1). The physiological role of this receptor, which is
persistently expressed by infiltrating leukocytes in different
chronic inflammatory diseases, has been studied in CD69-defi-
cient mice in multiple different models of chronic inflammation
(2–5). Thus, we have previously described that CD69/ mice
develop an exacerbated form of collagen-induced arthritis (CIA)
(3), a Th1 and Th17 cell-mediated autoimmune condition.More-
over, in an experimental model of autoimmune myocarditis
(EAM), CD69 negatively regulates cardiac inflammation through
the regulation of heart-specific Th17 responses (4). In this regard,
we have detected that CD69 modulates the in vitro differentiation
of T cells toward the Th17 lineage through the activation of the
Jak3/Stat5 inhibitory pathway (5). On the other hand, CD69 neg-
atively regulates the chemotactic responses of effector lympho-
cytes and dendritic cells (DCs) to sphingosine 1 phosphate (S1P);
CD69 can associate with S1P1 in the cell membrane and induce a
conformation of S1P1 that favors its internalization and degrada-
tion (6–8). It is clear that the identification of cellular ligands for
CD69 is a critical next step to better understand the physiological
role of this receptor.
Galectins are characterized by a common structural fold and a
conserved carbohydrate recognition domain (CRD) with a high
affinity for beta-galactosides (9). Despite being soluble proteins,
galectins are also expressed on the cell surface due to their associ-
ation with membrane glycoproteins. Thus, galectin-1 (Gal-1) is
expressed by most activated but not resting T and B cells, and it is
significantly upregulated in activated macrophages and T regula-
tory lymphocytes (10). In addition, tolerogenic DCs show a high
expression of Gal-1 (11), which is rapidly downregulated in re-
sponse to maturation signals. Furthermore, Gal-1-deficient DCs
show a greater immunogenic potential and an impaired ability to
halt the inflammatory phenomenon in a model of experimental
autoimmune encephalomyelitis (11). Altogether this evidence
suggests that Gal-1 expressed on DCs could act as a negative reg-
ulator of T cell differentiation. The beneficial effect of Gal-1 ad-
ministration in experimental models of T cell-mediated autoim-
mune disorders (12, 13) and graft-versus-host disease (14)
indicates that this galectin may be critical for T cell homeostasis
and peripheral tolerance. Gal-1-deficient (Lgals1/) mice show
augmented Th1 and Th17 responses and are considerably more
susceptible to immune-mediated fetal rejection and autoimmune
diseases than their wild-type (WT) counterparts (11, 15, 16). Ac-
cordingly, Th1 and Th17 lymphocytes express the cell surface gly-
cans critical for Gal-1-induced cell death (15).
Here, we demonstrate for the first time the presence of cell
membrane ligands for CD69 on human monocyte-derived DCs.
Mass spectrometry, surface plasmon resonance (SPR), and other
binding assays show that Gal-1 interacts specifically and directly
with CD69. The treatment with recombinant Gal-1 suppressed
human Th17 cell differentiation through its interaction with
CD69 expressed by activated T cells. Thus, our data indicate that
the expression of CD69 by activated T lymphocytes triggers an
anti-inflammatory mechanism mediated by Gal-1, which regu-
lates the immune response and prevents pathogenic Th17 re-
sponses.
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MATERIALS AND METHODS
Cells and reagents. The study was approved by the institutional review
board and the independent ethics committee of the Hospital Univer-
sitario de la Princesa and conformed to the Declaration of Helsinki
principles. Human monocyte-derived DCs were obtained as described
previously (17). At day 6, maturation of DCs was induced by lipopoly-
saccharide (LPS; 10 ng/ml; Sigma Chemical Co., St. Louis, MO).
Mouse bone marrow-derived DCs were generated as described previ-
ously (18). Langerhans cells (LCs) were isolated from a skin sample of
a healthy subject. Skin cell suspensions were obtained after epidermis
and dermis separation with trypsin. The epidermis was then cultured
overnight; nonadherent cells that migrated out the tissue into the me-
dium were collected. Human peripheral myeloid DCs (mDCs) were
purified from peripheral blood mononuclear cells by cell sorting ac-
cording to next staining: lineage negative (CD3, CD14, CD19,
CD20, and CD56), HLA-DR, CD11c, and CD123. Murine
monoclonal antibodies (MAbs) specific for human CD69 (TP1/8, TP1/
33, TP1/55, TP1/22, and CH1.1) and Fab were generated and charac-
FIG1 Recombinant CD69 proteins bind to immatureDCs. (A) ACD69-GST fusion protein has the extracellular domain of CD69, the carbohydrate recognition
domain (CRD) and a short neck (N) fused to the Flag (F) tag, a thrombin cleavage site (T), and glutathione S-transferase (GST). The CD69-Fc recombinant
protein has the CRD of CD69 fused to the human immunoglobulin G3 Fc tail. (B) Electrophoresis gels under reduced and nonreduced conditions. Coomassie
staining for detection of recombinant CD69 proteins after their purification is shown. Arrow, dimeric proteins; lanesM,molecularmassmarkers (kDa) indicated
on the left. (C) Representative binding of recombinant CD69 proteins to humanmonocytes, PBLs, and iDCs from 5 independent experiments is shown. Analysis
was on a FACSCalibur flow cytometer. Filled histograms, human IgG3 or GST; empty histograms, CD69-Fc or CD69-GST. (D) CD69-Fc binding to human skin
LCs and peripheral CD16 myeloid DCs. CD69-Fc binding was evaluated on isolated LCs from skin samples and purified peripheral mDCs, as indicated in
Materials and Methods. Cells were analyzed on a FACSCanto flow cytometer. Data correspond to those from 1 out of 3 experiments that were done. (E) Dose
response of CD69-Fc binding to iDCs. Binding is represented as the mean fluorescence intensity (MFI) and was analyzed as described for panel C. Mean
fluorescence intensity values are represented on a linear scale. (F) Inhibition of CD69-Fc binding by anti-CD69 MAbs. CD69-Fc was preincubated with
anti-CD69MAbs directed against epitope E1 (TP1/33, TP1/55), epitope E2, epitope E3 (Fab andCH1.1), or isotype-matched controls (IgG1 and IgG2b) and then
added to DCs. Black line, CD69-Fc; gray line, CD69-Fc preincubated with the indicatedMAbs; filled histogram, control human IgG3. Histograms are represen-
tative of those from at least 5 independent experiments.
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terized as described previously (19) (20). Recombinant Gal-1, Gal-3,
and Gal-7 proteins were produced as described previously (21). The
source of Gal-1 is important for protein-protein binding experiments,
likely due to the presence of reducing agents during the purification
procedure; thus, we avoided the use of commercial galectins.
Mice. CD69-deficient mice were generated in the C57BL/6J genetic
background as described previously (5). C57BL/6-Tg (TcraTcrb)
425Cbn/J OTII mice expressing a T-cell receptor (TCR) specific for the
peptide from amino acids 323 to 339 of ovalbumin in the context of I-Ab
were purchased from The Jackson Laboratory, Bar Harbor, ME (stock
number 004194). OTII mice were backcrossed with CD69-deficient mice
in the C57BL/6 background (OTII knockout mice). Experimental proce-
dures were approved by the CNIC AnimalWelfare and Ethics Committee
and conducted in accordancewith institutional guidelines for the care and
experimental use of animals that comply with Spanish and European
Union guidelines.
GenerationofCD69recombinantproteins.CD69–Flag–glutathione
S-transferase (GST) was generated by PCR using full-length CD69 cDNA
as the template, and the Flag tag was engineered for attachment to the 5=
end of the entire extracellular domain of human CD69. The PCR product
was cloned into the baculovirus transfer vector pAcSecG2T (BDPharmin-
gen, CA) in frame with the GST open reading frame (ORF). CD69-Fc and
CD94-Fc were constructed by fusing the C-type lectin domain (CTLD) of
the respective human molecules with the Fc region of human IgG3, and
the fusion was cloned into the baculovirus transfer vector pAcGP67A.
These three recombinant proteins were purified from insect cell superna-
tants using a GSTrap FF column for CD69-Flag-GST and a protein G HP
column (Amersham, NJ) for CD69-Fc and CD94-Fc.
Flow cytometry and binding assays. For analyses of CD69 binding,
cells were first incubated with serum to block Fc receptors and then with
CD69-Fc for 1 h at 4°C (10g/ml), followed by staining with a secondary
fluorescein isothiocyanate- or phycoerythrin-labeled anti-human Fc
antibody (Jackson ImmunoResearch, CA). CD69-Flag-GST binding was
detected using an anti-Flag–biotin conjugate plus streptavidin R-phyco-
erythrin (Molecular Probes, OR). For blocking binding assays, recombi-
nantCD69 (10g/ml)was preincubated or notwith anti-CD69MAbs (20
g/ml) or recombinant galectins for 30 min at room temperature before
incubation with DCs. To detect the binding of Gal-1 to mouse T cells,
lymphocyteswere incubated for 30min at 4°Cwith biotinylatedGal-1 and
then with streptavidin-Alexa Fluor 647 (Molecular Probes). Where indi-
cated, lymphocytes were preincubated with lactose (Lac) for 30 min at
4°C. Cells were analyzed with a FACSCalibur or with a FACSCanto flow
cytometer, as indicated below.
Enzyme-linked immunosorbent assay (ELISA). High-binding 96-
well plates were coated for 1 h at 37°C with human recombinant Gal-1,
Gal-3, or Gal-7 (10g/ml), followed by a blocking step of 1 h at 37°Cwith
FIG 2 Identification of galectin-1 as a binding protein of CD69. (A) Identification of binding proteins in pulldown experiments performed with iDCs incubated
with either IgG3 (control) or CD69-Fc. CD69-Fc and IgG3were coupled to a photoactivatable biotin-labeledmoiety and then incubated with iDCs for 1 h. Upon
UVphotoactivation, iDCs were lysed and incubated with streptavidin-Dynabeads. Pulldown samples were resolved on a 12%polyacrylamide gel, and the gel was
stainedwith Coomassie blue. The indicated protein bands were sliced and subjected to in-gel trypsin digestion, and the resulting peptides were analyzed by liquid
chromatography-MS/MS using an LTQ-Orbitrap XL mass spectrometer. The proteins identified in the bands numbered in the gel are listed in the tables on the
right. (B) Western blot of the pulldown samples from CD69-Fc and IgG3 revealed with anti-Gal-1. CD69-Fc and IgG3 were coupled to a photoactivatable
biotin-labeledmoiety and then incubated with iDCs, as described for panel A. Pulldown samples were resolved by SDS-PAGE and transferred to a nitrocellulose
membrane. The results of 1 of 3 independent experiments are shown. (C, D) Confirmation of the specific presence of Gal-1 in CD69-Fc pulldown. The peptide
pool from the band was subjected to selected MS/MS ion monitoring to unequivocally confirm the presence of the Gal-1 peptide from its MS/MS spectrum (C)
and to quantify the abundance of this peptide in the pulldowns from IgG3 and CD69-Fc, revealing that it was present only in the latter (D).
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2% (wt/vol) bovine serum albumin, and then incubated for 1 h at 37°C
with CD69-Fc or IgG3 (2 g/ml). After extensive washing, biotinylated
anti-human Fc was added for 1 h at 37°C. Binding was detected with
peroxidase-labeled streptavidin.
Cellular adhesion assays. Jurkat cells and Jurkat cells expressing
CD69 (J1; JKCD69) were loaded with carboxyfluorescein diacetate suc-
cinimidyl ester (CFSE;Molecular Probes) and seeded at a density of 0.2
105 cells per well in 96-well plates precoated with recombinant Gal-1,
Gal-3, or Gal-7. Cells were incubated for the indicated times at 37°C, and
then, nonadherent cells were removed by gentle washing. The number of
adhered cells was quantified on a Fluorstar spectrofluorimeter.
Polarization of human and mouse Th17 cells. For human Th17 po-
larization, naive CD4 T cells were purified to a purity of 96% by im-
munomagnetic depletion with a human naive CD4 T cell isolation kit II
(Miltenyi Biotec, CA). Human CD4 T cells (1 106) were polarized as
described previously (22). Where indicated, plates were coated with re-
combinant Gal-1 (10g/ml), and anti-CD69 (TP1/55) or an isotype con-
trol (10g/ml) was added to the cultures. After 10 days, the percentage of
interferon (IFN)- and interleukin-17 (IL-17)-producing cells was ana-
lyzed by intracellular staining. Mouse naive CD4 T cells were isolated
from spleen and lymph nodes by negative selection using an auto-
MACSPro separator (Miltenyi Biotec) according to the manufacturer’s
instructions. For polyclonal activation, naive CD4 T cells (0.2  106
cells/well) were stimulated with plate-bound anti-CD3 (5 mg/ml) plus
CD28 (2 mg/ml) MAbs for 72 h. For Th17 differentiation, CD4 T cells
were also cultured for 5 days with anti-CD3 plus CD28 MAbs in the
presence of a cytokine and antibody combination appropriate for polar-
ization: recombinant murine IL-6 (rmIL-6; 20 ng/ml), recombinant mu-
rine IL-23 (20 ng/ml), recombinant human transforming growth factor
1 (10 ng/ml), anti-IFN- (10 mg/ml), and anti-IL-4 (10 mg/ml). Where
indicated, plates were coated with recombinant Gal-1 (10 g/ml). For
analysis of IL-17 production, activatedCD4T cells or fully differentiated
Th17 cells were restimulated with 50 ng/ml phorbol myristate acetate
(PMA) and 750 ng/ml ionomycin for 6 h. Cytokine production was
determined using a BD cytometric bead array for IL-17, followed by
flow cytometry analysis on a BD FACSCanto II cytometer or intracel-
lular staining. All cytokines and antibodies were purchased from R&D
Systems, MN.
Pulldown and biochemical assays. For the pulldown assay, CD69-Fc
and IgG3 were labeled with sulfo-SBED, a cross-linker reagent containing
a photoactivatable biotin residue (Pierce, IL). Human dendritic cells were
incubated with the biotin-labeled proteins for 1 h, and after UV photoac-
tivation, cells were lysed in 0.5% NP-40 containing phosphate and pro-
tease inhibitor cocktail (Complete; Roche, Mannheim, Germany). Pull-
downwas performed using streptavidin-Dynabeads for 3 h at 4°C. After 5
washes with lysis buffer, the beads were resuspended in Laemmli buffer
and resolved by SDS-PAGE. After staining with Coomassie blue, gel sam-
ples were digested in gel with trypsin, and the resulting peptides were
identified by mass spectrometry (MS) as described previously (23). Se-
lected tandem MS (MS/MS) ion monitoring was performed as described
previously (24). Primary antibodies for immunoblotting were goat poly-
clonal anti-Gal-1, anti-Gal-3, and anti-Gal-9 (R&D Systems, MN) and
monoclonal anti-Gal-1 (Vector Laboratories, CA).
Surface plasmon resonance.CD69-Fc orCD94-Fcwas covalently im-
mobilized to functionalized carboxymethylated dextran on a sensor chip.
The sensor chip surface was activated with a 4:1 molar ratio of 1-ethyl-3-
(3-dimethylpropyl)-carboiimide and N-hydroxysuccinimide in water.
Proteins were injected at	75 g/ml in sodium acetate (pH 4.0) until the
appropriate immobilization level was reached. Remaining active groups
were neutralizedwith ethanolamine. Solutions of Gal-1 or Gal-3 (purified
as described previously [21]) at the indicated concentrations in HBS-EP
(10mMHEPES, 150mMNaCl, 3mMEDTA, 0.005% [vol/vol] surfactant
P20) buffer were injected for 3 min over CD69-Fc and CD94-Fc flow cells
and allowed to dissociate for at least 3 min before regeneration with lac-
tose (50 mM). The flow cell with immobilized CD94-Fc was used as a
reference surface, and double referencing was performed. Kinetic param-
eters (ka and the dissociation constant [Kd]) and equilibrium dissociation
constants (KDs) were determined by nonlinear fitting of the sensorgrams
to a 1:1 interaction model (Langmuir fitting) using BIAevaluation soft-
ware (version 4.0.1).
FIG 3 Specific association of CD69 with galectin-1. (A) Human recombinant
galectins (10 g/ml) were precoated on 96-well plates, and then CD69-Fc or
IgG3 (10 g/ml) was added. The interaction of CD69-Fc or IgG3 was assessed
by ELISA. Bars correspond to the means 
 SDs of three experiments. *, P 
0.007 (t test) for CD69-Fc versus IgG3. (B) Increasing doses of recombinant
Gal-1 were coated on a plate, and the interaction of CD69-Fc or control IgG3
was detected, as described for panel A. O.D, optical density. (C) Results of
assays for adhesion of Jurkat cells (JK) or CD69-expressing Jurkat cells
(JKCD69) to recombinant galectins. Jurkat cells were loaded with CFSE and
seeded onto plates precoated with recombinant Gal-1, Gal-3, or Gal-7. Where
indicated, anti-CD69MAbTP1/33 was incubated with cells before its addition
to plates coated with galectins. The graph presents the mean
 SD of 3 inde-
pendent experiments. BSA, bovine serum albumin. *, P  0.007 by one-way
analysis of variance and the Bonferroni test.
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RESULTS
We generated two different recombinant proteins containing the
extracellular domain of human CD69 (CD69-GST and CD69-Fc;
Fig. 1A). Both recombinant proteins resolved as dimers by gel
electrophoresis under reducing and nonreducing conditions (Fig.
1B). CD69 chimeric proteins were able to bind to human imma-
turemonocyte-derivedDCs (iDCs) as well as primary Langerhans
cells (LCs) and human peripheral myeloid DCs, whereas no bind-
ing to other leukocyte cell types, such as monocytes or peripheral
blood lymphocytes, was detected (Fig. 1C and D). Furthermore,
blast T cells showed slight binding of CD69, while a binding signal
was not detected in activated B lymphocytes or a panel of human
cell lines (data not shown). The binding of CD69-Fc and CD69-
GST to iDCs was dose dependent (Fig. 1E and data not shown),
and the binding of recombinant proteinswas specifically inhibited
by anti-human CD69 MAbs (Fig. 1F). In these assays, only MAbs
directed to epitope E1were able to inhibit the binding of CD69-Fc
to iDCs (Fig. 1F), whereas anti-CD69 MAbs that recognize other
FIG 4 Binding of CD69-Fc to Gal-1 expressed on human DCs. (A) Surface expression of Gal-1, Gal-3, and Gal-7 in iDCs analyzed by flow cytometry. (B)
Expression of Gal-1, Gal-3, and Gal-7 in protein lysates from iDCs analyzed by immunoblotting. Total lysates of human keratinocytes (KC) were included as
controls. (C) Gal-1 expression on human skin Langerhans cells and peripheral CD16myeloid DCs. LCs were isolated from a skin sample of a healthy subject.
Peripheral mDCs were purified by cell sorting. After purification, mDCs were tested for CD69-Fc binding. Binding of CD69 tomDCs is shown. Continuous line,
Gal-1 expression; dotted line, Alexa Fluor 647–donkey anti-goat signal. (D) Gal-1 expression in iDCs stimulated with LPS or IL-10. Dotted line, isotype control.
(E) Representative binding of CD69-Fc to DCs exposed to IL-10 and LPS. Dotted lines, IgG3 binding. The data in panels A to E are from 1 out of 3 independent
experiments. (F) CD69-Fc binding to iDCs is prevented by preincubation with recombinant human Gal-1 (hGal-1). CD69-Fc was preincubated with 20 g/ml
human Gal-1, human Gal-3 (hGal-3), or human Gal-7 (hGal-7) before its addition to iDCs. Histograms are representative of those from 4 independent
experiments. Thick lines, CD69-Fc; thin lines, IgG3. (G) Inhibition of CD69-Fc binding by increasing doses of human Gal-1. Thick lines, CD69-Fc; thin lines,
IgG3. Data from 1 out of 2 experiments are shown. y axis values are percentages of maximum.
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epitopes (E2 and E3) or isotype control MAbs did not inhibit or
only partially blocked the binding of CD69 (Fig. 1F).
To identify the putative cellular ligands of CD69 expressed by
DCs, assays in which photoactivatable biotin-labeled CD69-Fc
was allowed to bind to iDCs under cross-linking conditions were
performed. CD69-Fc and IgG3 (as a control) pulldown samples
were resolved by polyacrylamide gel electrophoresis, and proteins
present in the Coomassie-stained bands were identified by mass
spectrometry; Gal-1 was identified in one of the bands from
CD69-Fc but not in the band from the control (Fig. 2A). Western
blotting from CD69-Fc pulldown corroborated the specific bind-
ing to Gal-1 (Fig. 2B). The specific interaction of Gal-1 with
CD69-Fcwas confirmed by performing selectedMS/MS ionmon-
itoring of a Gal-1-specific peptide (Fig. 2C and D).
The binding of CD69-Fc to different human recombinant ga-
lectins was tested by ELISA. CD69-Fc interacted with Gal-1,
whereas no binding to Gal-7 or Gal-3 was observed (Fig. 3A and
B). Jurkat cells expressing CD69 (JKCD69) also specifically inter-
acted with Gal-1, mediating their adhesion to plastic surfaces
coated with Gal-1, which was blocked with anti-CD69 MAb
(Fig. 3C).
Galectin expression was analyzed in human DCs using flow
cytometry andWestern blot assays (Fig. 4A and B). Expression of
Gal-1 andGal-3 but notGal-7was observed on the surface of iDCs
(Fig. 4A). Gal-1 was also expressed in primary LCs and peripheral
myeloid DCs (Fig. 4C) Interestingly, LPS treatment decreased the
expression of Gal-1 on iDCs, whereas the cytokine IL-10 exerted
the opposite effect (Fig. 4D). Accordingly, LPS stimulation re-
duced the binding of CD69-Fc, while preincubation with IL-10
enhanced it (Fig. 4E). The binding of CD69-Fc to iDCs was pre-
vented by the addition of soluble recombinantGal-1 but notGal-3
or Gal-7 (Fig. 4F and G).
The results of assays of the binding of CD69-Fc to iDCs in the
presence of lactose or thiodigalactoside (TDG) (Fig. 5A) suggested
that the interaction with Gal-1 is influenced by carbohydrates.
Surface plasmon resonance (SPR) analysis using a Biacore biosen-
sor demonstrated a direct interaction between CD69 and Gal-1
(Fig. 5B). The presence of lactose (50 mM) inhibited the binding
of Gal-1 to CD69-Fc (Fig. 5B), indicating that carbohydrate moi-
eties contribute to this interaction. Gal-1 did not bind C-type
lectin CD94-Fc (Fig. 5C), and Gal-3 did not interact with immo-
bilized CD69-Fc, confirming the binding specificity (Fig. 5D). Ki-
netic experiments showed that the response with CD69-Fc immo-
bilized on the sensor chip was augmented with increasing
concentrations of human Gal-1, and the data could be fitted to a
1:1 binding model with a Kd of 96 nM (Fig. 5E).
We then explored the possible functional consequences of the
CD69–Gal-1 association. As shown in Fig. 6A and B, recombinant
Gal-1 was able to inhibit IFN-- and IL-17-producing cells in a
Th17 polarization culture, a phenomenon that was blocked with
the anti-CD69 MAb TP1/55. Accordingly, the inhibitory effect of
Gal-1 on the mRNA levels of RORC2, a key Th17 transcription
factor, was also reverted by the anti-CD69MAb TP1/55 (Fig. 6C).
In contrast, an isotype-matched antibody did not affect Th17 cell
FIG 5 Direct and carbohydrate-dependent interaction on CD69 to Gal-1. (A) CD69-Fc binding to iDCs is dependent on carbohydrate recognition. Binding
assays were performed in the presence or absence of 50 mM lactose (Lac), 2 mM thiodigalactoside (TDG), or 50 mM saccharose (Sac). Dotted lines, carbohy-
drates; thick lines, CD69-Fc; thin lines, IgG3. The results of 1 out of 3 experiments are shown. y axis values are percentages of maximum. (B to E) SPR analysis
of the interaction between CD69 and galectin-1. Differential surface plasmon resonance was performed over a surface coated with either CD69-Fc or CD94-Fc,
and the sensorgrams show the normalized response (in relative units [RU]) to CD69-Fc/CD94-Fc. (B) Two different concentrations of Gal-1 (3.0 and 1.0 M)
were injected for 3 min over CD69-Fc and CD94-Fc flow cells, and after a 3-min dissociation, 50 mM lactose (1 min) was injected. (C) Control SPR analysis of
the lack of interaction of CD94-Fc and Gal-1. Differential surface plasmon resonance was performed over a surface coated with CD94-Fc. (D) Gal-1 and Gal-3
(3.0 M) were injected through both flow cells, as described for panel B. (E) Kinetic experiment. Increasing concentrations of Gal-1 (0.15 to 3.0 M) were
injected through both flow cells, and the kinetic constant was obtained from mathematical fitting.
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differentiation in either the absence or the presence of Gal-1. In
addition, MAb TP1/55 alone did not exert any effect on the per-
centage of CD4 IL-17-positive or IFN--positive T cells. At the
low dose employed (10 g/ml), no significant Gal-1-induced
apoptosis or loss of viability was observed (data not shown).
Gal-1 ligands are absent from naive mouse T cells but highly
expressed on activated CD4 T cells in lymph nodes (LNs) drain-
ing antigen-sensitive skin (25). To assess the possible association
of Gal-1 with CD69 in mouse cells, we performed binding assays
with naive and PMA-activated CD4 T cells fromWT and CD69-
deficient mice. We found that recombinant Gal-1 did not interact
with resting CD4 T cells but bound to PMA-activated lympho-
cytes. In addition, activated T cells from CD69/ mice showed
decreased binding of Gal-1 compared with activated WT T cells
(Fig. 6D). As expected, Gal-1 binding was inhibited by lactose
(Fig. 6E). To further assess the role of the CD69/Gal-1 interaction
in mouse IL-17 production, Th differentiation was carried out
using CD69-deficient T cells. Recombinant Gal-1 was able to in-
hibit Th17 differentiation in a Th17 polarization culture of WT
CD4T cells, while CD69-deficient cells were unresponsive to the
Gal-1 effect (Fig. 6F). Thus, Gal-1 binds mouse CD69, and this
associationmodulates the differentiation ofmouse Th17 lympho-
cytes.
DISCUSSION
The leukocyte activation receptor CD69 controls inflammation in
several autoimmune processes by limiting the differentiation of
Th17 pathogenic cells. However, full elucidation of the functional
role of CD69 in immune responses in vivo has constantly been
hampered by the unknown identity of the CD69 ligand(s). In this
FIG 6 Human Th17 cell differentiation is regulated by the Gal-1–CD69 association. (A) Analysis of intracellular IFN- and IL-17 expression by flow cytometry.
Human naive CD4 T cells were differentiated toward effector Th17 cells in the presence of the indicated stimuli. After 10 days, the percentages of IFN-- and
IL-17-producing cells were analyzed. (B) The bar charts represent the means
 SDs of 4 independent experiments of total CD4 IL-17-positive T cells obtained
with the different stimuli. (C) Reverse transcription-PCR analysis of the transcription factor RORC2 in differentiated Th17 cells. Induc., induction. *, P 0.04
by one-way analysis of variance and the Bonferroni test. (D) CD4 T cells isolated from LNs of CD69 OTII knockout (KO) or OTII WT mice were stimulated
with PMA and incubated with biotinylated Gal-1 for 30min at 4°C. After staining with streptavidin-Alexa Fluor 647, cells were analyzed by flow cytometry. Bars
correspond to means 
 SDs of Gal-1 binding, represented as the geometric mean (GM) fluorescence intensity (n  3). (E) Gal-1 binding to activated
lymphocytes is inhibited by Lac. LN lymphocytes were preincubated with Lac for 30 min at 4°C, and Gal-1 binding was analyzed. Strept, streptavidin. (F) Naive
CD4 T cells (0.2  106 cell/well) were cultured with anti-CD3 (5 mg/ml) plus anti-CD28 (2 mg/ml) MAbs in the presence of a cytokine and antibody
combination appropriate for Th17 polarization. Where indicated, recombinant Gal-1 (10 g/ml) was included. The percentage of cells producing IL-17 was
determined by intracellular staining.
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study, we identified Gal-1 to be a ligand for CD69. Transfection
assays, blocking antibodies, and pulldown, proteomic, and SPR
studies demonstrated that Gal-1 but not other galectins binds to
the extracellular domain of CD69. Gal-1 is expressed by DCs, and
its expression is upregulated by tolerogenic stimuli correlating
with increased binding of the extracellular domain of CD69 to
these cells. We have identified a key function for CD69 in the
regulation of both mouse and human Th17 effector cells through
the interaction with Gal-1.
CD69belongs to theC-type lectin superfamily and is amember
of the NK receptor family (1). The ligands of a number of NK
receptors have recently been identified and characterized, includ-
ing Nkrp1d and Nkrp1f (26, 27), lectin-like transcript 1 (LLT1)
(28), and NKp80 (also called KLRF1) (29); some of these ligands
are lectins (30). However, the ligand(s) for CD69 has remained
elusive, although it has been postulated to involve carbohydrate
moieties (31, 32). Remarkably, our data demonstrate the associa-
tion of CD69 with Gal-1. CD69 contains sites for N-glycosylation
(33), and conceivably, the interaction of Gal-1 with CD69 may
involve carbohydrate recognition. Indeed, our data show that in
the presence of lactose, CD69 binding to iDCs is partially inhib-
ited. SPR studies not only confirmed the direct and specific inter-
action of CD69 with Gal-1 but also demonstrated that this
interaction is influenced by carbohydrates. Other additional
membrane glycoproteins, besides CD69, have been reported to be
binding partners of Gal-1 in T cells, including CD2, CD3, CD4,
CD7, CD43, CD45, CD90, and Thy-1 (34–37). Some of these
Gal-1 partners have been described to be responsible for apoptosis
induction in T cells. Our results show that addition of low con-
centrations of Gal-1 inhibits Th17 differentiation through CD69
interaction on activated T cells. However, this suppressive effect is
not due to Gal-1-induced apoptosis. Thus, besides the induction
of apoptosis, nonapoptotic mechanisms might contribute to the
immunosuppressive effects of this protein. In accord with this,
similar results were observed when low concentrations of Gal-1–
human Fc were incubated with human skin-resident memory T
cells, which dramatically lowered the numbers of IL-17-produc-
ing T cells (25). Depending on the dose of recombinant Gal-1
treatment, the effects could be different (25, 37). In this regard, an
irreversible dimeric form of Gal-1 is a potent inducer of apoptosis
in T cells (38). Recently, the Gal-1 associationwith CD45 has been
reported to modulate IL-10 (39). However, our data provide an
unequivocal explanation for Gal-1 regulation of Th17 differenti-
ation through the interaction with CD69.
We have previously reported that CD69/ mice develop an
exacerbated form of autoimmune disease due to an enhanced in-
flammatory response associatedwithTh17 lymphocytes. This reg-
ulatory effect of CD69 is mediated, at least in part, through the
activation of the Jak3/Stat5 signaling pathway, which inhibits
Th17 differentiation (5). Although the putative mechanism that
triggers the regulatory effect mediated by CD69 remains to be
established, we have previously proposed the existence of a cellu-
lar ligand for CD69 on antigen-presenting cells (APCs) at specific
times or in specific cell subsets (i.e., tolerogenic DCs) (40). Our
results demonstrate that DC-expressed Gal-1 fulfills these criteria
as a counterreceptor for CD69 and that this ligand-receptor pair
represents a novel regulatory pathway for the control of inflam-
mation and immune-mediated tissue damagemediated largely by
Th17 cells. Thus, our data further support the suggestion that
CD69 is a therapeutic target in inflammation (40) and reinforces
the potential for Gal-1 to be an immunomodulatory agent.
In summary, we have identified for the first time a cellular
counterreceptor for CD69 which exerts a relevant functional role,
mainly in the differentiation of Th17 lymphocytes. These data
significantly contribute to our understanding of the pathophysi-
ological role of CD69 and further confirm the relevance of its
immune-regulatory effect.
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